Raltitrexed

Laboratory experiments with cancer cells reveal two ways in which tumors evade drugs designed to starve and kill them, a new study shows. NEW YORK, Nov. 26, 2024 /PRNewswire/ -- While chemotherapies successfully treat cancers and extend patients' lives, they are known not to work for everyone for long, as cancer cells rewire the process by which they convert fuel into energy (metabolism) to outmaneuver the drugs' effects. Many of these drugs are so-called antimetabolics, disrupting cell processes needed for tumor growth and survival. Three such drugs used in the study — raltitrexed, N-(phosphonacetyl)-l-aspartate (PALA), and brequinar — work to prevent cancer cells from making pyrimidines, molecules that are an essential component to genetic letter codes, or nucleotides, that make up RNA and DNA. Cancer cells must have access to pyrimidine supplies to produce more cancer cells and to produce uridine nucleotides, a primary fuel source for cancer cells as they rapidly reproduce, grow, and die. Disrupting the fast-paced but fragile pyrimidine synthesis pathways, as some chemotherapies are designed to do, can rapidly starve cancer cells and spontaneously lead to them dying (apoptosis). Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the new study shows how cancer cells survive in an environment made hostile by the persistent shortage of the energy from glucose (the chemical term for blood sugar) needed to drive tumor growth. This better understanding of how cancer cells evade the drugs' attempts to kill them in a low-glucose environment, the researchers say, could lead to the design of better or more effective combination therapies. Publishing in the journal Nature Metabolism online Nov. 26, study results showed that the low-glucose environment inhabited by cancer cells, or tumor microenvironment, stalls cancer cell consumption of existing uridine nucleotide stores, making the chemotherapies less effective. Normally, uridine nucleotides would be made and consumed to help make the genetic letter codes and fuel cell metabolism. But when DNA and RNA construction is blocked by these chemotherapies, so too is the consumption of uridine nucleotide pools, the researchers found, as glucose is needed to change one form of uridine, UTP, into another usable form, UDP-glucose. The irony, researchers say, is that a low-glucose tumor microenvironment is in turn slowing down cellular consumption of uridine nucleotides and presumably slowing down rates of cell death. Researchers say cancer cells need to run out of pyrimidine building blocks, including uridine nucleotides, before the cells will self-destruct. In other experiments, low-glucose tumor microenvironments were also unable to activate two proteins, BAX and BAK, sitting on the surface of mitochondria, a cell's fuel generator. Activation of these trigger proteins disintegrates the mitochondria, and instantly sets off a series of caspase enzymes that help initiate apoptosis (cell death). "Our study shows how cancer cells manage to offset the impact of low-glucose tumor microenvironments, and how these changes in cancer cell metabolism minimize chemotherapy's effectiveness," said study lead investigator Minwoo Nam, PhD, a postdoctoral fellow in the Department of Pathology at NYU Grossman School of Medicine and Perlmutter Cancer Center. "Our results explain what has until now been unclear about how the altered metabolism of the tumor microenvironment impacts chemotherapy: low glucose slows down the consumption and exhaustion of uridine nucleotides needed to fuel cancer cell growth and hinders resulting apoptosis, or death, in cancer cells," said senior study investigator Richard Possemato, PhD. Possemato is an associate professor in the Department of Pathology at NYU Grossman School of Medicine and also a member of Perlmutter Cancer Center. Possemato, who is also coleader of the Cancer Cell Biology Program at Perlmutter, says his team's study results could one day be used to develop chemotherapies or combination therapies that would change or trick cancer cells into responding the same way in a low-glucose microenvironment as they would in an otherwise stable glucose microenvironment. He also says that diagnostic tests could be developed to measure how a patient's cancer cells would most likely respond to low-glucose microenvironments and to predict how well a patient might respond to a particular chemotherapy. Possemato says his team has plans to investigate how blocking other cancer cell pathways might trigger apoptosis in response to these chemotherapies. Some experimental drugs, such as Chk-1 and ATR inhibitors, already exist that might accomplish this, he notes, but more need to be investigated because Chk-1 and ATR inhibitors are not well tolerated by patients. For the study, researchers performed a scan of 3,000 cancer cell genes known to be involved in cell metabolism to determine, by deletion, which were necessary for cancer cell survival after chemotherapy. Most of the genes they found that were essential to cell survival in low-glucose tumor environments were also involved in pyrimidine synthesis, a precise biological pathway targeted by many chemotherapies. This focused their experiments on how different lab-grown clones of cancer cells responded to low-glucose after chemotherapy and what other chemical processes were impacted by depressed sugar levels. Funding support for the study was provided by National Institutes of Health grants P30CA016087, R01CA286141, R01CA214948, R01GM132491, and R35GM139610. Additional funding support came from the Pew Charitable Trusts, Alexander and Margaret Stewart Trust, and the American Cancer Society. Besides Nam and Possemato, other NYU Langone researchers involved in this study are co-investigators Wenxin Xia, Abdul Hannan Mir, and Tony Huang. Media Inquiries: David March 212-404-3528 [email protected] STUDY LINK WILL BECOME ACTIVE AFTER EMBARGO LIFTS: STUDY DOI: 10.1038/s42255-024-01166-w SOURCE NYU Langone Health System WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

精彩内容 7月23日，CDE官网显示，南京正大天晴的1类新药NTQ3617片获得临床试验默示许可，拟用于MTAP缺失的晚期恶性实体肿瘤患者。米内网数据显示，2023年中国公立医疗机构终端抗肿瘤药销售额超过1100亿元。 1类新药NTQ3617片的临床试验申请于2024年5月28日获得CDE承办受理，7月23日获得临床试验默示许可，拟用于MTAP缺失的晚期恶性实体肿瘤患者。 米内网数据显示，近年来中国城市公立医院、县级公立医院、城市社区中心及乡镇卫生院（简称中国公立医疗机构）终端抗肿瘤药（化药+生物药）销售额均达千亿规模，2023年超过1100亿元，同比增长3.96%，创下新高。 中国公立医疗机构终端抗肿瘤药销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局 在抗肿瘤领域，南京正大天晴已有8款仿制药注射用硼替佐米、注射用盐酸伊达比星、甲磺酸仑伐替尼胶囊、注射用右雷佐生、瑞戈非尼片、培唑帕尼片、注射用盐酸吉西他滨、注射用雷替曲塞获批上市。 NTQ3617片是今年以来南京正大天晴首款获批临床的1类新药，目前公司已有3款抗肿瘤1类新药NTQ2494片、NTQ1062片、NTQ3617片处于获批临床及以上研究阶段。 资料来源：米内网数据库、CDE注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。 本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。 投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。 把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下： 【分享、点赞、在看】点一点不失联哦